Kharmoum Saoussane, Najdi Adil, Rahhali Rabie, Meliani Meryem, Boutayeb Saber, Mrabti Hind, El Ghissassi Ibrahim, Afqir Said, Mellas Naoufal, Ichou Mohamed, El M'Rabet Fatima Zahra, Errihani Hassan
Université Mohamed V Suissi Rabat , service d'oncologie médicale, centre hospitalier universitaire de Tanger, Maroc.
Université Abdelmalek-Essadi, faculté de médecine et de pharmacie de Tanger, département d'épidémiologie et recherche clinique, Tetouen, Maroc.
Bull Cancer. 2021 Oct;108(10):940-947. doi: 10.1016/j.bulcan.2021.04.019. Epub 2021 Jul 17.
Oral anticancer therapy is becoming increasingly developed; their prescription has become a common practice in oncology. However, there is a variability and diversity in prescription practice. Its magnitude has been very little studied in scientific literature. To our knowledge, this is the first study in Morocco and North Africa to evaluate the practice of prescribing oral chemotherapy.
The authors conducted a national exhaustive cross-sectional survey, to evaluate the practice of the oral chemotherapy "Capecitabine" type prescription by Moroccan oncologists and to identify strategies to promote an adherence to oral anti-neoplasic therapy.
Ninety-one medical oncologists answered out of 118, from public oncology centres (29.7%), Hospital University (58.2%), and private sector (12.1%). Thirty-four of the oncologists replied by email, 33 through phone conversation and 24 by filling paper questionnaires. In total, 32% of the cases were handwritten prescriptions, and 51.6% electronically generated. Forty-six percent of medical oncologists dedicated more time to the oral chemotherapy type Capecitabine prescription versus its intravenous equivalent 5FU. However, 33% medical oncologists take less time to this prescription, and 20.9% of them take the same time. Adherence to oral chemotherapy was evaluated by simply questioning of patients in most of the cases (94%) and 4% of medical oncologist declared that they did not evaluate this adherence. In total, 87.9% of Moroccan medical oncologists revealed that they have not received any specific training in the therapeutic education of the patient with oral anti-cancer treatment.
In Morocco, there is a great variability in prescription and follow-up practice for patients receiving oral chemotherapy. There is a lack of a national standardization with regards to the procedures of prescribing and monitoring patients to ensure the quality and safety of the oral chemotherapy prescription.
口服抗癌疗法日益发展,其处方在肿瘤学领域已成为常见做法。然而,处方实践存在变异性和多样性。科学文献中对其程度的研究甚少。据我们所知,这是摩洛哥和北非第一项评估口服化疗处方实践的研究。
作者开展了一项全国性详尽横断面调查,以评估摩洛哥肿瘤学家开具口服化疗药物“卡培他滨”类处方的实践,并确定促进口服抗肿瘤治疗依从性的策略。
118名肿瘤学家中,91名做出回应,他们来自公立肿瘤中心(29.7%)、大学医院(58.2%)和私营部门(12.1%)。34名肿瘤学家通过电子邮件回复,33名通过电话交谈回复,24名通过填写纸质问卷回复。总体而言,32%的病例为手写处方,51.6%为电子生成处方。46%的肿瘤内科医生在开具卡培他滨类口服化疗处方时比开具其静脉等效药物5氟尿嘧啶花费更多时间。然而,33%的肿瘤内科医生在该处方上花费时间较少,20.9%的医生花费时间相同。在大多数情况下(94%),通过简单询问患者来评估口服化疗的依从性,4%的肿瘤内科医生宣称他们未评估这种依从性。总体而言,87.9%的摩洛哥肿瘤内科医生表示他们未接受过关于口服抗癌治疗患者治疗教育的任何特定培训。
在摩洛哥,接受口服化疗患者的处方和随访实践存在很大变异性。在处方和监测患者的程序方面缺乏国家标准,以确保口服化疗处方的质量和安全性。